Clinical Trial

Aspirin in Subclinical Coronary Artery Disease: A Pilot Randomised Controlled Trial

Study acronym: ASCAD-P
Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
In patients with subclinical coronary artery disease, the ASCAD-P study aims to assess the feasibility of a larger phase 3 pragmatic randomized controlled trial comparing prescription versus no prescription of low-dose aspirin in routine clinical practice.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2026-04-05; most recent amendment 2026-05-07.
Trial Details
NCT Number NCT07524335
Lead Sponsor Montreal Heart Institute
Conditions Coronary Artery Disease, Subclinical Atherosclerotic Cardiovascular Disease
Enrollment 48 participants
Start Date 2026-05-01
Primary Completion 2027-05-01 (estimated)
Study Completion 2028-05-01 (estimated)
Updated on ClinicalTrials.gov 2026-05-12